Machine Learning-based Identification of a Cell Death-related Signature Associated with Prognosis and Immune Infiltration in Glioma

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2024 Jun 7

PMID 38847472

Authors

Quanwei Zhou

Fei Wu

Wenlong Zhang

Youwei Guo

Xingjun Jiang

Xuejun Yan

Yiquan Ke

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence suggests that a wide variety of cell deaths are deeply involved in cancer immunity. However, their roles in glioma have not been explored. We employed a logistic regression model with the shrinkage regularization operator (LASSO) Cox combined with seven machine learning algorithms to analyse the patterns of cell death (including cuproptosis, ferroptosis, pyroptosis, apoptosis and necrosis) in The Cancer Genome Atlas (TCGA) cohort. The performance of the nomogram was assessed through the use of receiver operating characteristic (ROC) curves and calibration curves. Cell-type identification was estimated by using the cell-type identification by estimating relative subsets of known RNA transcripts (CIBERSORT) and single sample gene set enrichment analysis methods. Hub genes associated with the prognostic model were screened through machine learning techniques. The expression pattern and clinical significance of MYD88 were investigated via immunohistochemistry (IHC). The cell death score represents an independent prognostic factor for poor outcomes in glioma patients and has a distinctly superior accuracy to that of 10 published signatures. The nomogram performed well in predicting outcomes according to time-dependent ROC and calibration plots. In addition, a high-risk score was significantly related to high expression of immune checkpoint molecules and dense infiltration of protumor cells, these findings were associated with a cell death-based prognostic model. Upregulated MYD88 expression was associated with malignant phenotypes and undesirable prognoses according to the IHC. Furthermore, high MYD88 expression was associated with poor clinical outcomes and was positively related to CD163, PD-L1 and vimentin expression in the in-horse cohort. The cell death score provides a precise stratification and immune status for glioma. MYD88 was found to be an outstanding representative that might play an important role in glioma.

References

Zhu G, Cheng Z, Huang Y, Zheng W, Yang S, Lin C . MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF‑κB/AP‑1 signaling pathway. Int J Mol Med. 2019; 45(1):131-140. PMC: 6889924. DOI: 10.3892/ijmm.2019.4390. View

Guo Q, Xiao X, Zhang J . MYD88 Is a Potential Prognostic Gene and Immune Signature of Tumor Microenvironment for Gliomas. Front Oncol. 2021; 11:654388. PMC: 8059377. DOI: 10.3389/fonc.2021.654388. View

Su Y, Zhao B, Zhou L, Zhang Z, Shen Y, Lv H . Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett. 2020; 483:127-136. DOI: 10.1016/j.canlet.2020.02.015. View

Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T . Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017; 19(6):786-795. PMC: 5464432. DOI: 10.1093/neuonc/now285. View

Zhang M, Xiao J, Liu J, Bai X, Zeng X, Zhang Z . Calreticulin as a marker and therapeutic target for cancer. Clin Exp Med. 2022; 23(5):1393-1404. DOI: 10.1007/s10238-022-00937-7. View

Chen L, Zheng L, Chen P, Liang G . Myeloid Differentiation Primary Response Protein 88 (MyD88): The Central Hub of TLR/IL-1R Signaling. J Med Chem. 2020; 63(22):13316-13329. DOI: 10.1021/acs.jmedchem.0c00884. View

Huang L, Zhang L, Chen X . Updated review of advances in microRNAs and complex diseases: experimental results, databases, webservers and data fusion. Brief Bioinform. 2022; 23(6). DOI: 10.1093/bib/bbac397. View

Zeng F, Wang K, Liu X, Zhao Z . Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma. Cell Commun Signal. 2020; 18(1):2. PMC: 6943920. DOI: 10.1186/s12964-019-0492-6. View

Zheng Y, Ji Q, Xie L, Wang C, Yu C, Wang Y . Ferroptosis-related gene signature as a prognostic marker for lower-grade gliomas. J Cell Mol Med. 2021; 25(6):3080-3090. PMC: 7957186. DOI: 10.1111/jcmm.16368. View

10.

Pan H, Pan J, Li P, Gao J . Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer. Clin Immunol. 2022; 238:109019. DOI: 10.1016/j.clim.2022.109019. View

11.

Feng E, Liang T, Wang X, Du J, Tang K, Wang X . Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples. J Neuroinflammation. 2019; 16(1):33. PMC: 6373026. DOI: 10.1186/s12974-019-1418-3. View

12.

Sacco A, Battaglia A, Botta C, Aversa I, Mancuso S, Costanzo F . Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response. Cells. 2021; 10(2). PMC: 7913036. DOI: 10.3390/cells10020303. View

13.

Tang H, Wang Y, Chlewicki L, Zhang Y, Guo J, Liang W . Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell. 2016; 29(3):285-296. PMC: 4794755. DOI: 10.1016/j.ccell.2016.02.004. View

14.

Fan Y, Peng X, Li B, Zhao G . Development of Autophagy Signature-Based Prognostic Nomogram for Refined Glioma Survival Prognostication. Biomed Res Int. 2020; 2020:1872962. PMC: 7492900. DOI: 10.1155/2020/1872962. View

15.

Hu J, Shi B, Liu X, Jiang M, Yuan C, Jiang B . The activation of Toll-like receptor 4 reverses tumor differentiation in human glioma U251 cells via Notch pathway. Int Immunopharmacol. 2018; 64:33-41. DOI: 10.1016/j.intimp.2018.08.019. View

16.

Egunsola A, Zawislak C, Akuffo A, Chalmers S, Ewer J, Vail C . Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88. Cell Immunol. 2011; 272(2):220-9. PMC: 3244535. DOI: 10.1016/j.cellimm.2011.10.008. View

17.

Qu S, Liu S, Qiu W, Liu J, Wang H . Screening of autophagy genes as prognostic indicators for glioma patients. Am J Transl Res. 2020; 12(9):5320-5331. PMC: 7540153. View

18.

Tang D, Kang R, Vanden Berghe T, Vandenabeele P, Kroemer G . The molecular machinery of regulated cell death. Cell Res. 2019; 29(5):347-364. PMC: 6796845. DOI: 10.1038/s41422-019-0164-5. View

19.

Yan J, Wan P, Choksi S, Liu Z . Necroptosis and tumor progression. Trends Cancer. 2021; 8(1):21-27. PMC: 8702466. DOI: 10.1016/j.trecan.2021.09.003. View

20.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View